, Volume 11, Issue 3, pp 230–232 | Cite as

Expression of somatostatin receptors may guide the use of somatostatin receptor imaging and therapy in differentiated thyroid cancer

  • Giorgio TregliaEmail author
  • Guido Rindi
  • Vittoria Rufini

Key words

Differentiated thyroid cancer Endocrine tumors Imaging Nuclear medicine Somatostatin analogues Somatostatin receptors Therapy 


  1. 1.
    American Thyroid Association (ATA) Guidelines Task-force on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM, Haugen BR, et al, 2009 Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19: 1167–1214.CrossRefGoogle Scholar
  2. 2.
    Ambrosini V, Fani M, Fanti S, Forrer F, Maecke HR, 2011 Radiopeptide imaging and therapy in Europe. J Nucl Med 52: Suppl 2: 42–55.CrossRefGoogle Scholar
  3. 3.
    Treglia G, Castaldi P, Rindi G, Giordano A, Rufini V, 2012 Diagnostic performance of Gallium-68 somatostatin receptor PET and PET/CT in patients with thoracic and gastroenteropancreatic neuroendocrine tumours: a meta-analysis. Endocrine 42: 80–87.CrossRefPubMedGoogle Scholar
  4. 4.
    Papotti M, Kumar U, Volante M, Pecchioni C, Patel YC, 2001 Immunohistochemical detection of somatostatin receptor types 1–5 in medullary carcinoma of the thyroid. Clin Endocrinol 54: 641–649.CrossRefGoogle Scholar
  5. 5.
    Pazaitou-Panayiotou K, Tiensuu Janson E, Koletsa T, et al, 2012 Somatostatin receptor expression in non medullary thyroid carcinomas. Hormones [E-pub ahead of print]Google Scholar
  6. 6.
    Sancak S, Hardt A, Singer J, et al, 2010 Somatostatin receptor 2 expression determined by immunohistochemistry in cold thyroid nodules exceeds that of hot thyroid nodules, papillary thyroid carcinoma, and Graves’ disease. Thyroid 20: 505–511.CrossRefPubMedGoogle Scholar
  7. 7.
    Müssig K, Wehrmann T, Dittmann H, et al, 2012 Expression of the proliferation marker Ki-67 associates with tumour staging and clinical outcome in differentiated thyroid carcinomas. Clin Endocrinol. DOI: 10.1111/j.1365-2265.2012.04343.x.Google Scholar
  8. 8.
    Klagge A, Krause K, Schierle K, Steinert F, Dralle H, Fuhrer D, 2010 Somatostatin receptor subtype expression in human thyroid tumours. Horm Metab Res 42: 237–240.CrossRefPubMedGoogle Scholar
  9. 9.
    Druckenthaner M, Schwarzer C, Ensinger C, et al, 2007 Evidence for Somatostatin receptor 2 in thyroid tissue. Regul Pept 138: 32–39.CrossRefPubMedGoogle Scholar
  10. 10.
    Forssell-Aronsson EB, Nilsson O, Bejegård SA, et al, 2000 111In-DTPA-D-Phe1-octreotide binding and so-matostatin receptor subtypes in thyroid tumors. J Nucl Med 41: 636–642.PubMedGoogle Scholar
  11. 11.
    Ain KB, Taylor KD, Tofiq S, Venkataraman G, 1997 Somatostatin receptor subtype expression in human thyroid and thyroid carcinoma cell lines. J Clin Endocrinol Metab 82: 1857–1862.PubMedGoogle Scholar
  12. 12.
    Giammarile F, Houzard C, Bournaud C, Hafdi Z, Sassolas G, Borson-Chazot F, 2004 Diagnostic management of suspected metastatic thyroid carcinoma: clinical value of octreotide scintigraphy in patients with negative high-dose radioiodine scans. Eur J Endocrinol 150: 277–283.CrossRefPubMedGoogle Scholar
  13. 13.
    Christian JA, Cook GJ, Harmer C, 2003 Indium-111-labelled octreotide scintigraphy in the diagnosis and management of non-iodine avid metastatic carcinoma of the thyroid. Br J Cancer 89: 258–261.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Stokkel MP, Reigman HI, Verkooijen RB, Smit JW, 2003 Indium-111-Octreotide scintigraphy in differentiated thyroid carcinoma metastases that do not respond to treatment with high-dose I-131. J Cancer Res Clin Oncol 129: 287–294.PubMedGoogle Scholar
  15. 15.
    Görges R, Kahaly G, Müller-Brand J, Mäcke H, Roser HW, Bockisch A, 2001 Radionuclide-labeled somatostatin analogues for diagnostic and therapeutic purposes in nonmedullary thyroid cancer. Thyroid 11: 647–659.CrossRefPubMedGoogle Scholar
  16. 16.
    Haslinghuis LM, Krenning EP, De Herder WW, Reijs AE, Kwekkeboom DJ, 2001 Somatostatin receptor scintigraphy in the follow-up of patients with differentiated thyroid cancer. J Endocrinol Invest 24: 415–422.CrossRefPubMedGoogle Scholar
  17. 17.
    Valli N, Catargi B, Ronci N, et al, 1999 Evaluation of indium-111 pentetreotide somatostatin receptor scintigraphy to detect recurrent thyroid carcinoma in patients with negative radioiodine scintigraphy. Thyroid 9: 583–589.CrossRefPubMedGoogle Scholar
  18. 18.
    Tisell LE, Ahlman H, Wängberg B, et al, 1999 Expression of somatostatin receptors in oncocytic (Hürthle cell) neoplasia of the thyroid. Br J Cancer 79: 1579–1582.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Garin E, Devillers A, Le Cloirec J, et al, 1998 Use of indium-111 pentetreotide somatostatin receptor scintigraphy to detect recurrent thyroid carcinoma in patients without detectable iodine uptake. Eur J Nucl Med 25: 687–694.CrossRefPubMedGoogle Scholar
  20. 20.
    Baudin E, Schlumberger M, Lumbroso J, Travagli JP, Caillou B, Parmentier C, 1996 Octreotide scintigraphy in patients with differentiated thyroid carcinoma: contribution for patients with negative radioiodine scan. J Clin Endocrinol Metab 81: 2541–2544.PubMedGoogle Scholar
  21. 21.
    Kohlfuerst S, Igerc I, Gallowitsch HJ, et al, 2006 Is there a role for sandostatin treatment in patients with progressive thyroid cancer and iodine-negative but somatostatin-receptor-positive metastases? Thyroid 16: 1113–1119.CrossRefPubMedGoogle Scholar
  22. 22.
    Rodrigues M, Li S, Gabriel M, Heute D, Greifeneder M, Virgolini I, 2006 99mTc-depreotide scintigraphy versus 18F-FDG-PET in the diagnosis of radioiodine-negative thyroid cancer. J Clin Endocrinol Metab 91: 3997–4000.CrossRefPubMedGoogle Scholar
  23. 23.
    Gabriel M, Froehlich F, Decristoforo C, et al, 2004 99mTc-EDDA/HYNIC-TOC and (18)F-FDG in thyroid cancer patients with negative (131)I whole-body scans. Eur J Nucl Med Mol Imaging 31: 330–341.CrossRefPubMedGoogle Scholar
  24. 24.
    Traub-Weidinger T, Von Guggenberg E, Dobrozemsky G, et al, 2010 Preliminary experience with (68)Ga-DOTA-lanreotide positron emission tomography. Q J Nucl Med Mol Imaging 54: 52–60.PubMedGoogle Scholar
  25. 25.
    Gabriel M, Andergassen U, Putzer D, et al, 2010 Individualized peptide-related-radionuclide-therapy concept using different radiolabelled somatostatin analogs in advanced cancer patients. Q J Nucl Med Mol Imaging 54: 92–99.PubMedGoogle Scholar
  26. 26.
    Teunissen JJ, Kwekkeboom DJ, Kooij PP, Bakker WH, Krenning EP, 2005 Peptide receptor radionuclide therapy for non-radioiodine-avid differentiated thyroid carcinoma. J Nucl Med 46: Suppl 1: 107–114.Google Scholar
  27. 27.
    Waldherr C, Schumacher T, Pless M, et al, 2001 Radio-peptide transmitted internal irradiation of non-iodophil thyroid cancer and conventionally untreatable medullary thyroid cancer using. Nucl Med Commun 22: 673–678.CrossRefPubMedGoogle Scholar

Copyright information

© Hellenic Endocrine Society 2012

Authors and Affiliations

  1. 1.Institute of Nuclear MedicineCatholic University of the Sacred HeartRomeItaly
  2. 2.Institute of PathologyCatholic University of the Sacred HeartRomeItaly

Personalised recommendations